Navigation Links
Children's Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach
Date:7/21/2008

Chicago, IL, Children's Memorial Hospital of Chicago announced today that it has received a grant from BioMarin Pharmaceutical Inc. to support its Adult Phenylketonuria (PKU) Outreach Education Project. The goal of the program is to conduct outreach to PKU patients who are no longer being treated at PKU clinics to encourage them to return for further education about recent developments in the management and treatment of PKU.

"According to our records, approximately 250 PKU patients are not currently being seen in our clinic on a regular basis. This illustrates the magnitude of the problem and suggests that there may be as many patients currently outside the healthcare system as there are receiving care," said Barbara Burton, M.D., Director, PKU and Metabolic Disease Clinic, Children's Memorial Hospital, Chicago. "Untreated PKU can have severe neurological implications, including impaired cognitive function, mood disorders, mental illness and brain damage. Through specific targeting efforts, we hope to reach out to patients who are not receiving care to educate them about new options and advances in the treatment of PKU so that they can learn to manage and possibly avoid the severe neurological implications associated with untreated disease."

The goal of the project is to connect with each PKU and hyperphe patient not currently receiving care and encourage them to attend educational sessions arranged by Children's Memorial on the treatment of PKU and maternal PKU. The program will also identify additional outreach strategies that are most effective in reaching adult PKU patients who can benefit from new management guidelines and techniques.

"We are very pleased to provide this grant to Children's Memorial Hospital in support of this pilot program," said Steve Aselage, Senior Vice President of Global Commercial Development at BioMarin. "It's an important campaign and we applaud Dr. Burton and her team for proactively reaching out
'/>"/>

Contact: Julie Pesch
jpesch@childrensmemorial.org
773-880-3055
Children's Memorial Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema
2. Northwestern Memorial trial may wean kidney transplant patients off antirejection drugs
3. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
4. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
5. 3 out of 4 hospital patients suffer from malnutrition regardless of their pathology
6. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
7. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
8. Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
9. Childrens Hospital neurosurgeon receives grant
10. Pennsylvania Hospital recognized for excellence in bariatric surgery
11. Texas Hospital nations first to use large-scale cocoon strategy against whooping cough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... 2015-2019"  report to their offering. One ... technology. With continuous advances in technology, it is important ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... N.M., Feb. 19, 2013A study by researchers from Los Alamos ... direct-acting antiviral agent in development for the treatment of hepatitis ... the fastest viral decline ever seen with anti-HCV drugs ... C virus affects about 150 million people worldwide. It is ...
... and higher education institutions is developing a network for ... help doctors to diagnose different types of possible cancerous ... The seven partners across four European countries, Spain, ... project, known as BIOPOOL, with a budget of 2,500,000 ...
... PARK, Pa. Identifying areas of malarial infection ... on the average monthly temperatures, according to a ... may also apply to environmentally temperature-dependent organisms other ... key driver of several of the essential mosquito ...
Cached Biology News:Computer modeling reveals how surprisingly potent hepatitis C drug works 2Data pooling in biobanks: The BIOPOOL project 2New approach alters malaria maps 2
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... July 7 Silence Therapeutics plc (AIM: SLN) ... United States patent 7,750,144, titled Methods and Compositions ... the United States Patent and Trademark Office (USPTO).  The ... (RNAi) agents having decreased off-target silencing activity through certain ...
... development of future molecular devices, new display technologies, and ... to play a primary role. ... interlocked structures that consist of a dumbell-shaped molecule whose ... behave as molecular "machines," with the ring moving along ...
... XIANYANG, China , July ... ) ("Biostar" or "the Company"), the,Xianyang-based manufacturer of a ... other pharmaceutical products, today,announced that Mr. Deyin "Bill" ... July 1, 2010 . Mr. Chen replaces Ms. ...
Cached Biology Technology:Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent 2Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent 3Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent 4Study measures single-molecule machines in action 2Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 2Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 3
...
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Template and primers for preparation of internal control spots...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
Biology Products: